Xin Lang Cai Jing·2026-01-30 08:57Group 1 - The article discusses the transition of biotech companies to biopharma, emphasizing that biopharma companies have sales revenues sufficient to cover operational and future R&D costs [1][17][18] - It highlights the valuation differences between biotech and biopharma, noting that the value of a single pipeline at a 20% net margin is approximately equal to its peak sales, while post-acquisition by MNCs, the market value can reach 2-3 times [1][18] - The analysis includes companies like Innovent Biologics, Hengrui Medicine, and BeiGene to observe the relationship between biopharma's market value, revenue scale, and R&D capabilities [1][18] Group 2 - Innovent Biologics has transitioned from biotech to biopharma, requiring sales revenue to cover management, sales, and R&D expenses, with a minimum revenue target of 6 billion RMB [2][18] - The projected revenues for Innovent Biologics from 2022 to 2024 are 45.56 billion, 62.06 billion, and 94.22 billion RMB, respectively, with a net profit expected to turn positive by 2025 [3][19] - The company’s market value fluctuated between 429.12 billion and 875.89 billion RMB during this transition period [4][20] Group 3 - Hengrui Medicine is identified as a mature biopharma leader, with revenue and net profit figures for 2022 to 2025 showing consistent growth [5][21] - The revenue for Hengrui Medicine is projected to be 212.75 billion, 225.2 billion, and 279.85 billion RMB for 2022, 2023, and 2024, respectively, with a net profit of 39.06 billion RMB in 2022 [6][22] - The market value of Hengrui Medicine is expected to range from 2,286.46 billion to 4,723.01 billion RMB by 2025, reflecting its strong operational performance [7][22] Group 4 - BeiGene is characterized as an aggressive biopharma, with R&D expenses consistently exceeding 10 billion RMB, necessitating a revenue of at least 541.18 billion RMB to normalize its profit statement [8][23] - The projected revenues for BeiGene from 2022 to 2025 are 95.664 billion, 174.23 billion, and 272.14 billion RMB, with a peak market value of 3,535.05 billion HKD in 2025 [9][24] - Despite higher revenues, BeiGene's market value remains lower than Hengrui Medicine due to its abnormal profit statement [8][24] Group 5 - The article also discusses the valuation of Kangfang Biologics, which is projected to have a revenue of 64 billion RMB to normalize its profit statement, with a reasonable market value estimated between 640 billion and 1,024 billion HKD [10][25] - The revenue for Kangfang Biologics is expected to be 14.12 billion RMB in the first half of 2025, reflecting a growth of 33.67% [11][26] - The market value fluctuation for Kangfang Biologics in 2025 is anticipated to be between 454.17 billion and 1,504.50 billion RMB, indicating expectations of reaching breakeven as a biopharma [12][27] Group 6 - The article concludes that for companies transitioning from biotech to biopharma, a revenue range of 60-100 billion RMB and a market value of 500-1,000 billion RMB are significant benchmarks [28] - Initial assessments suggest that Innovent Biologics may be undervalued, while Kangfang Biologics' market value reflects expectations of overseas clinical approvals [28] - BeiGene's revenue surpasses that of Hengrui Medicine, yet its market value remains lower due to profit statement anomalies, indicating the need for further detailed research [28]